Similar Search Results

Making Do in Making Drugs : Innovation Policy and Pharmaceutical Manufacturing

Price II, W. Nicholson - 2016

far behind the innovative manufacturing found in other industries. This lack of innovation in drug manufacturing stands in … stark contrast to the innovation present in drug discovery. Drug discovery is the focus of a calibrated innovation policy … dollars and in human lives. This article addresses the previously underappreciated role of manufacturing in innovation studies …

Persistent link: https://www.econbiz.de/10014038452

Opportunities and barriers for innovation and entrepreneurship in orphan drug development

Belousova, Olga A.; Groen, Aard J.; Ouendag, Aniek M. - In: Technological forecasting & social change : an … 161 (2020), pp. 1-11

Persistent link: https://www.econbiz.de/10012533698

Expected Profits and the Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing today in exchange for incentives for firms to …

Persistent link: https://www.econbiz.de/10012838413

Calculating the Costs and Benefits of Advance Preparations for Future Pandemics

Glennerster, Rachel; Snyder, Christopher M.; Tan, … - National Bureau of Economic Research - 2022

The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...

Persistent link: https://www.econbiz.de/10013435127

An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics

Snyder, Christopher M.; Hoyt, Kendall; Gouglas, Dimitrios - National Bureau of Economic Research - 2022

We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price...

Persistent link: https://www.econbiz.de/10013462668

Taiwan's pharmaceuticals : a failure of the sectoral system of innovation?

Hu, Mei-chih; Hung, Shih-Chang - In: Technological forecasting & social change : an … 88 (2014), pp. 162-176

Persistent link: https://www.econbiz.de/10010483232

Research and innovation for drug development in neglected diseases : a case study of India

Bhattacharya, Sujit; Pushkaran, Jayanthi A. - In: African journal of science, technology, innovation & … 3 (2011) 3, pp. 236-258

Persistent link: https://www.econbiz.de/10009731729

Governing innovative science : challenges facing the commercialization of plant-made pharmaceuticals

Smyth, Stuart; Khachatourians, George K.; Phillips, … - In: International trade and policies for genetically …, (pp. 133-146). 2006

Persistent link: https://www.econbiz.de/10003326914

How pharmaceutical innovation evolves : the path from science to technological development to marketable drugs

Wang, Xuefeng; Zhang, Shuo; Liu, Yuqin; Du, Jian; … - In: Technological forecasting & social change : an … 167 (2021), pp. 1-12

Persistent link: https://www.econbiz.de/10012801454

Mapping the strength of sectoral innovation system in the Nigerian pharmaceutical industry : empirical evidence

Ayo-Lawal, Rachael Aderonke; Adelowo, Caleb Muyiwa; … - In: African journal of science, technology, innovation and … 15 (2023) 2, pp. 198-210

Persistent link: https://www.econbiz.de/10014251267

1
2
3
4
5
6
7
8
9
10
Next
Last